Spinal Cord Disorders is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Spinal Cord Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Spinal Cord Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Spinal Cord Disorders overview
Spinal cord disorders encompass a range of conditions affecting the spinal cord, resulting in disruptions to its function and potentially causing sensory, motor, or autonomic nerve impairments. These disorders include spinal cord injuries, spinal stenosis, herniated discs, tumors, infections, or inflammatory conditions like multiple sclerosis. Symptoms vary widely based on the specific disorder but may involve pain, weakness, numbness, tingling sensations, difficulty walking, and bladder or bowel dysfunction. Diagnosis involves imaging studies, neurological examinations, and sometimes electrophysiological tests. Treatment approaches aim to manage symptoms, prevent further damage, and may involve medications, physical therapy, assistive devices, surgery, or other interventions tailored to the specific spinal cord disorder and its impact on an individual’s functionality.
For a complete picture of PTSR and LoA scores for drugs in Spinal Cord Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
